Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2024-11-20 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
DIRECTOR/PDMR SHAREHOLDING
Foreign Filer Report
2024-11-20 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is titled 'RNS Number : 0131N' and explicitly details a 'Transaction by Person Discharging Managerial Responsibilities' (PDMR), specifically a purchase of American Depositary Shares (ADSs) by a Non-Executive Director, Tony Mok. This type of insider transaction reporting, mandated by regulations like the EU Market Abuse Regulation (MAR), directly corresponds to the definition of Director's Dealing. The filing code for Director's Dealing is DIRS.
2024-11-20 English
TAGRISSO RECOMMENDED FOR EU APPROVAL - LAURA
Foreign Filer Report
2024-11-18 English
Tagrisso recommended for EU approval - LAURA
Regulatory Filings Classification · 1% confidence The document begins with 'RNS Number : 5095M' and contains standard regulatory boilerplate language at the end, including references to RNS, the London Stock Exchange, and the Financial Conduct Authority. The content is a press release announcing a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding the EU approval recommendation for the drug Tagrisso. This type of announcement, which is a formal regulatory update disseminated via the RNS system but does not fit neatly into specific financial reporting categories (like 10-K, ER, or DIV), is best classified as a general Regulatory Filing or Announcement. Since 'RNS' is defined as the fallback for miscellaneous regulatory announcements, it is the most appropriate code.
2024-11-18 English
DIRECTOR/PDMR SHAREHOLDING
Foreign Filer Report
2024-11-15 English
Director/PDMR Shareholding
Director's Dealing Classification · 1% confidence The document is explicitly labeled with an 'RNS Number' and contains a 'Transaction by Person Discharging Managerial Responsibilities' (PDMR) detailing the purchase of shares by a Non-Executive Chair. This type of mandatory disclosure regarding insider transactions, often filed via the London Stock Exchange's RNS system, falls under regulatory reporting. While it relates to director dealings (DIRS), the primary context here is the regulatory announcement mechanism itself, which is often captured by the general regulatory filing code or the specific insider trading code if available. Since the definitions provided include 'Director's Dealing (Code: DIRS)' and the content is purely about a director's transaction, DIRS is the most specific fit. The presence of the RNS header suggests it is a regulatory filing, but DIRS is more precise than RNS (the fallback). The document length is short, but it is the primary disclosure, not an announcement *about* the disclosure.
2024-11-15 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.